肝癌人源肿瘤异种移植模型 z-bo 2021-11-29 378

　　Objective: To establish a xenotransplantation model of human liver cancer and explore its role in precision medicine for liver cancer.

　　 Method: Take fresh surgical resection specimens of clinical liver cancer, NCG mice are subcutaneously inoculated with tumor tissue to establish a PDX model, and HE staining compares the consistency of the morphological structure of the transplanted tumor tissue and the patient's tumor tissue. The PDX model successfully passed to the third generation was used to prepare tumor cell suspension, BALB/c nude mice were subcutaneously inoculated to make 15 liver cancer xenograft models. After tumor formation, they were randomly divided into 5-fluorouracil (5-fluorouracil, 5-FU) group , Sorafenib group and negative control group, 5 in each group. Regularly monitor the tumor volume and weight of each group of tumor-bearing mice, calculate the tumor inhibition rate according to the tumor weight, and evaluate the efficacy.

　　 Results: In this study, a total of 6 PDX models of liver cancer were established, and the success rate was 33.3% (6/18). The model maintained the characteristics of the primary tumor. In 1 case of PDX model, the tumor inhibition rates of 5-FU and sorafenib groups were 63.7% and 29.6%, respectively. There was a significant difference in the tumor inhibition rate of 5-FU group (P<0.05), sorafenib group There was no statistically significant difference in tumor inhibition rate, which was consistent with clinical results.

　　 Conclusion: The PDX model of liver cancer maintains the histological morphology of the patient's tumor tissue and can be applied to precision medicine for patients with liver cancer.